查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606614

大肠直肠癌筛检和诊断市场：按产品类型、年龄层和最终用途划分 - 全球预测 2025-2030

Colorectal Cancer Screening & Diagnostic Market by Product Type (Instruments, Reagents & Kits), Age Group (19 to 65, Above 65, Upto 18 Years), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年大肠癌筛检和诊断市值为152.9亿美元，预计到2024年将达到162.1亿美元，复合年增长率为6.28%，到2030年将达到234.3亿美元，预计将达到1000万美元。

大肠直肠癌筛检和诊断市场的范围和定义包括旨在早期检测和诊断结直肠癌的各种方法和技术，这对于有效治疗和改善患者预后至关重要。这个市场包括大肠镜检查、大便潜血试验(FOBT)、柔性乙状结肠镜检查等测试，以及基于 DNA 的粪便检验等新型非侵入性方法。需要这些筛检和诊断方法是因为大肠癌的高盛行率和死亡率，特别是在 50 岁以上的人群和有家族病史的人群中。主要应用包括早期检测无症状个体和监测确诊患者的疾病进展，最终用户包括医院、诊断实验室和门诊病人护理中心。该市场的推动因素包括公众意识的提高、生物技术的进步以及强调预防性医疗保健的政府支持政策。人工智慧辅助诊断成像和家庭检测套组等技术创新带来了快速成长的机会，与保险公司的合作可以增加可及性。然而，该市场面临一些限制，例如患者对侵入性手术的焦虑、高成本和可变的测试准确性。市场开拓面临的挑战包括新兴市场的监管障碍和有限的医疗基础设施。创新领域包括开发具有成本效益的微创测试、开发基于遗传见解的个人化筛检通讯协定以及整合用于病患监测的数位健康工具。这个市场的竞争本质需要持续的研发投入来改善。为了实现业务成长，公司应专注于策略伙伴关係、提高检测准确性，并扩展到医疗保健支出预计会增加的新兴市场。为了克服这些挑战，我们需要解决医疗保健差异、提高意识、降低相关成本并争取更广泛的采用。

主要市场统计
基准年[2023] 152.9亿美元
预计年份 [2024] 162.1亿美元
预测年份 [2030] 234.3亿美元
复合年增长率（%） 6.28%

市场动态：快速发展的结直肠癌筛检和诊断市场的关键市场洞察

供需的动态交互作用正在改变大肠直肠癌筛检和诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球大肠直肠癌患者数量增加
    • 政府不断采取措施促进大肠直肠癌的早期发现
  • 市场限制因素
    • 大肠癌筛检和诊断相关的高成本
  • 市场机会
    • 增加医疗保健领域癌症诊断和治疗的资金和支出
    • 增加新的和先进的癌症诊断技术的推出
  • 市场挑战
    • 对大肠镜检查后併发症的担忧

波特五力：开拓大肠直肠癌筛检与诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对大肠直肠癌筛检和诊断市场的影响

外部宏观环境因素在塑造结直肠癌筛检和诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解大肠直肠癌筛检和诊断市场的竞争格局

对大肠直肠癌筛检和诊断市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵大肠直肠癌筛检与诊断市场供应商绩效评估

FPNV定位矩阵是评估大肠直肠癌筛检和诊断市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，描绘结直肠癌筛检和诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，结直肠癌筛检和诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球大肠直肠癌病例不断增加
      • 政府加大力度促进大肠直肠癌早期发现
    • 抑制因素
      • 大肠直肠癌筛检和诊断相关的高成本
    • 机会
      • 增加医疗保健部门用于癌症诊断和治疗的资金和支出
      • 更多采用新的先进癌症诊断技术
    • 任务
      • 对大肠镜检查后併发症的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章大肠癌筛检与诊断市场：依产品类型

  • 装置
  • 试剂和套件

第七章大肠直肠癌筛检与诊断市场：依年龄组

  • 19-65岁
  • 65岁以上
  • 直到 18 岁

第八章大肠直肠癌筛检和诊断市场：依最终用途分类

  • 临床实验室
  • 影像诊断中心
  • 医院/诊所

第九章北美和南美大肠癌筛检和诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区大肠直肠癌筛检与诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲大肠癌筛检与诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Guardant Health
  • Hologic, Inc.
  • Illumina, Inc.
  • KARL STORZ SE & Co. KG
  • Medtronic PLC
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novigenix SA
  • Olympus Corporation
  • Prenetics Global Limited
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AF41

The Colorectal Cancer Screening & Diagnostic Market was valued at USD 15.29 billion in 2023, expected to reach USD 16.21 billion in 2024, and is projected to grow at a CAGR of 6.28%, to USD 23.43 billion by 2030.

The scope and definition of the colorectal cancer screening and diagnostic market encompass a range of methods and technologies aimed at early detection and diagnosis of colorectal cancer, which is essential for effective treatment and improved patient outcomes. This market includes tests such as colonoscopy, fecal occult blood testing (FOBT), flexible sigmoidoscopy, and newer non-invasive methods like DNA-based stool tests. The necessity for these screening and diagnostic methods stems from the high prevalence and mortality rates associated with colorectal cancer, particularly among individuals aged 50 and older or those with a family history of the disease. Key applications include early detection in asymptomatic individuals and monitoring disease progression in diagnosed patients, with end-users spanning hospitals, diagnostic laboratories, and outpatient care centers. The market is driven by factors such as increasing public awareness, advancements in biotechnology, and supportive government policies emphasizing preventive healthcare. Technological innovations such as AI-assisted imaging and at-home testing kits represent burgeoning opportunities, while collaboration with insurance companies can enhance accessibility. However, the market faces limitations like patient apprehension towards invasive procedures, high costs, and variability in test accuracy. Market growth is challenged by regulatory hurdles and limited healthcare infrastructure in developing regions. Areas of innovation include the development of cost-effective and minimally invasive tests, personalized screening protocols based on genetic insights, and integration of digital health tools for patient monitoring. The nature of this market is competitive, with ongoing R&D investments required for improvements. For business growth, companies should focus on strategic partnerships, enhancing test accuracy, and expanding into emerging markets where increased healthcare spending is anticipated. Overcoming challenges calls for addressing healthcare disparities, promoting increased awareness, and reducing associated costs for broader adoption.

KEY MARKET STATISTICS
Base Year [2023] USD 15.29 billion
Estimated Year [2024] USD 16.21 billion
Forecast Year [2030] USD 23.43 billion
CAGR (%) 6.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Colorectal Cancer Screening & Diagnostic Market

The Colorectal Cancer Screening & Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing cases of colorectal cancer globally
    • Rising government initiatives to promote early detection of colorectal cancer
  • Market Restraints
    • High cost associated with colorectal cancer screening and diagnostic
  • Market Opportunities
    • Growing funding and expenditure in the healthcare sector for cancer diagnosis and treatment
    • Increase in the launch of new and advanced cancer diagnostic technologies
  • Market Challenges
    • Concerns associated with post-colonoscopy complications

Porter's Five Forces: A Strategic Tool for Navigating the Colorectal Cancer Screening & Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Colorectal Cancer Screening & Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Colorectal Cancer Screening & Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Colorectal Cancer Screening & Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Colorectal Cancer Screening & Diagnostic Market

A detailed market share analysis in the Colorectal Cancer Screening & Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Colorectal Cancer Screening & Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Colorectal Cancer Screening & Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Colorectal Cancer Screening & Diagnostic Market

A strategic analysis of the Colorectal Cancer Screening & Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Colorectal Cancer Screening & Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Clinical Genomics Technologies Pty Ltd., Eiken Chemical Co., Ltd., Epigenomics AG, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Guardant Health, Hologic, Inc., Illumina, Inc., KARL STORZ SE & Co. KG, Medtronic PLC, Merck KGaA, Myriad Genetics, Inc., Novigenix SA, Olympus Corporation, Prenetics Global Limited, QIAGEN N.V., Quest Diagnostics Incorporated, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Colorectal Cancer Screening & Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Instruments and Reagents & Kits.
  • Based on Age Group, market is studied across 19 to 65, Above 65, and Upto 18 Years.
  • Based on End-use, market is studied across Clinical Laboratories, Diagnostic Imaging Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of colorectal cancer globally
      • 5.1.1.2. Rising government initiatives to promote early detection of colorectal cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with colorectal cancer screening and diagnostic
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing funding and expenditure in the healthcare sector for cancer diagnosis and treatment
      • 5.1.3.2. Increase in the launch of new and advanced cancer diagnostic technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with post-colonoscopy complications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Colorectal Cancer Screening & Diagnostic Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Kits

7. Colorectal Cancer Screening & Diagnostic Market, by Age Group

  • 7.1. Introduction
  • 7.2. 19 to 65
  • 7.3. Above 65
  • 7.4. Upto 18 Years

8. Colorectal Cancer Screening & Diagnostic Market, by End-use

  • 8.1. Introduction
  • 8.2. Clinical Laboratories
  • 8.3. Diagnostic Imaging Centers
  • 8.4. Hospitals & Clinics

9. Americas Colorectal Cancer Screening & Diagnostic Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Colorectal Cancer Screening & Diagnostic Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Colorectal Cancer Screening & Diagnostic Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. Bayer AG
  • 4. Becton, Dickinson and Company
  • 5. Bio-Rad Laboratories, Inc.
  • 6. bioMerieux SA
  • 7. Clinical Genomics Technologies Pty Ltd.
  • 8. Eiken Chemical Co., Ltd.
  • 9. Epigenomics AG
  • 10. Exact Sciences Corp.
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Fujifilm Holdings Corporation
  • 13. GE HealthCare Technologies, Inc.
  • 14. Guardant Health
  • 15. Hologic, Inc.
  • 16. Illumina, Inc.
  • 17. KARL STORZ SE & Co. KG
  • 18. Medtronic PLC
  • 19. Merck KGaA
  • 20. Myriad Genetics, Inc.
  • 21. Novigenix SA
  • 22. Olympus Corporation
  • 23. Prenetics Global Limited
  • 24. QIAGEN N.V.
  • 25. Quest Diagnostics Incorporated
  • 26. Siemens AG
  • 27. Sysmex Corporation
  • 28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET RESEARCH PROCESS
  • FIGURE 2. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY 19 TO 65, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ABOVE 65, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY UPTO 18 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023